[Experience with e new water soluble contrast medium for lumbar myelography (author's transl)].
Meglumin-Iodrinat has been synthesized as the contrasting part of Myelografin by Schering AG. and tested for lumbar Myelography in animal experiments. The excellent neural and general compatibility justified a first clinical trial. 200 patients were examined, 100 each with following upright or lying down positions. There were no local symptoms, no signs of spinal or cerebral irritation. This is seen to be the main advantage compared with drugs used so far. Intensity of contrast corresponded with that of Conray 60 and Dimer X. The most common complaints like headache and nausea were interpreted as CSF hypotension and can be clearly reduced by lying down. Also the concentration of the contrastmedium diminishes more rapidly with the patient lying down.
D000818:Animals; D003287:Contrast Media / Q000009:adverse effects*; D004285:Dogs; D004361:Drug Tolerance; D000882:Haplorhini; D006801:Humans; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging*; D009192:Myelography / Q000379:methods; D010215:Papio; D011187:Posture; D011817:Rabbits; D012995:Solubility
D003287:Contrast Media
Erfahrungen mit einem neuen wasserlöslichen Kontrastmittel für die lumbale Myelographie (Vergleichende Untersuchungen mit anschliessend aufrechter oder liegender Position)